Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: Similarities and differences

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 485-493

  Smalberg, Jasper H ^a   Kruip, Marieke J H A ^a   Janssen, Harry L A ^a   Rijken, Dingeman C ^a   Leebeek, Frank W G ^a   De Maat, Moniek P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Budd Chiari syndrome; coagulation; fibrinolysis; portal vein thrombosis; pulmonary embolism; site specificity; venous thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; PHOSPHOLIPID ANTIBODY; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AGE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BUDD CHIARI SYNDROME; CANCER PATIENT; DEEP VEIN THROMBOSIS; ERYTHROMELALGIA; FIBRINOLYSIS; GENE MUTATION; GENETIC RISK; HEMOGLOBINURIA; HEMOSTASIS; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; HYPOFIBRINOLYSIS; INJURY; LUNG EMBOLISM; MYELOPROLIFERATIVE DISORDER; NEOPLASM; OBESITY; ORAL CONTRACEPTION; PATHOPHYSIOLOGY; PORTAL VEIN THROMBOSIS; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK FACTOR; SPLANCHNIC BLOOD FLOW; SPLANCHNIC VEIN THROMBOSIS; SURGERY; THROMBOPHILIA;

BUDD-CHIARI SYNDROME; FIBRINOLYSIS; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MYELOPROLIFERATIVE DISORDERS; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 79952155338     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.213371     Document Type: Article

References (115)

1. Goldhaber SZ, Tapson VF, Committee DFS. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259-262. (Pubitemid 38058748)
2. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611-1617. (Pubitemid 41716546)
3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692-699. (Pubitemid 46563566)
4. Oger E. Incidence of venous thromboembolism: a community-based study in Western France: EPI-GETBP Study Group, Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83: 657-660.
5. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005;365: 1163-1174. (Pubitemid 40417567)
6. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost. 2009;35:468-477.
7. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44:62-69. (Pubitemid 46553809)
8. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729-1764.
9. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999; 353:1167-1173. (Pubitemid 29155221)
10. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527-1535. (Pubitemid 32429213)
11. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19-25. (Pubitemid 38801482)
12. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
13. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143: 321-335.
14. Mahmoodi BK, Brouwer JL, Ten Kate MK, Lijfering WM, Veeger NJ, Mulder AB, Kluin-Nelemans HC, Van Der Meer J. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010;8:1193-1200.
15. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67. (Pubitemid 24144355)
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703. (Pubitemid 26383091)
17. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
18. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
19. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526. (Pubitemid 36976716)
20. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352-2361. (Pubitemid 40676757)
21. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624-628. (Pubitemid 27182953)
22. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost. 1996;75:229-232. (Pubitemid 26081472)
23. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ, American College of Chest P. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:110S-112S. (Pubitemid 351892962)
24. Lijfering WM, Middeldorp S, Veeger NJ, Hamulyak K, Prins MH, Buller HR, van der Meer J. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation. 2010;121:1706-1712.
25. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet. 2000;356:182-183. (Pubitemid 30446970)
26. van Stralen KJ, Doggen CJ, Bezemer ID, Pomp ER, Lisman T, Rosendaal FR. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol. 2008;28:1872-1877.
27. Farmer-Boatwright MK, Roubey RA. Venous thrombosis in the antiphospholipid syndrome. Arterioscler Thromb Vasc Biol. 2009;29: 321-325.
28. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002;99:2720-2725. (Pubitemid 34525357)
29. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296:397-402. (Pubitemid 44127523)
30. Lutsey PL, Folsom AR, Heckbert SR, Cushman M. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost. 2009;7:1639-1648.
31. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138:769-774. (Pubitemid 47313221)
32. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008;6:1720-1725.
33. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem. 2008;54:2042-2048. (Pubitemid 352774038)
34. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327-1333. (Pubitemid 352016312)
35. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 2009;7:4-13.
36. Guimaraes AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, Rijken DC, Leebeek FW. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol. 2009;145: 115-120.
37. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105:1102-1105. (Pubitemid 40170881)
38. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med. 2008;5:e97.
39. Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC. Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost. 2010;8:605-607.
40. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182-1189. (Pubitemid 34522408)
41. Crowther MA, Roberts J, Roberts R, Johnston M, Stevens P, Skingley P, Patrassi GM, Sartori MT, Hirsh J, Prandoni P, Weitz JI, Gent M, Ginsberg JS. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost. 2001;85: 390-394. (Pubitemid 32233006)
42. Folsom AR, Cushman M, Heckbert SR, Rosamond WD, Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol. 2003;56:598-603. (Pubitemid 36842919)
43. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation. 1992;85:1822-1827.
44. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010;116:113-121.
45. Folkeringa N, Coppens M, Veeger NJ, Bom VJ, Middeldorp S, Hamulyak K, Prins MH, Buller HR, van der Meer J. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost. 2008;100:38-44. (Pubitemid 351948743)
46. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859. (Pubitemid 30235895)
47. Libourel EJ, Bank I, Meinardi JR, Balje-Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Buller HR, van der Meer J. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica. 2002;87:1068-1073. (Pubitemid 35192219)
48. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA. Thrombinactivatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103:3773-3776. (Pubitemid 38596294)
49. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol. 2006;134:92-94. (Pubitemid 43830033)
50. Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med. 2002;126:1376-1381. (Pubitemid 36237287)
51. Favier R, Aoki N, de Moerloose P. Congenital α(2)-plasmin inhibitor deficiencies: a review. Br J Haematol. 2001;114:4-10. (Pubitemid 32702626)
52. Leebeek FW, Knot EA, Ten Cate JW, Traas DW. Severe thrombotic tendency associated with a type I plasminogen deficiency. Am J Hematol. 1989;30:32-35. (Pubitemid 19022735)
53. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ III. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248. (Pubitemid 34595030)
54. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb. 2008;36:131-136.
55. Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. Semin Thromb Hemost. 2006;32: 694-699. (Pubitemid 44623376)
56. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5: 632-634. (Pubitemid 46680709)
57. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128: 275-290. (Pubitemid 40216149)
58. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126:338S-400S. (Pubitemid 39302602)
59. Gabay C, Kushner I. Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340: 448-454. (Pubitemid 29084777)
60. Beam DM, Courtney DM, Kabrhel C, Moore CL, Richman PB, Kline JA. Risk of thromboembolism varies, depending on category of immobility in outpatients. Ann Emerg Med. 2009;54:147-152.
61. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med. 2008;168:21-26.
62. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978-980. (Pubitemid 41297761)
63. Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med. 2005;5:48-55. (Pubitemid 40721045)
64. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364-371. (Pubitemid 36286552)
65. Rajani R, Melin T, Bjornsson E, Broome U, Sangfelt P, Danielsson A, Gustavsson A, Grip O, Svensson H, Loof L, Wallerstedt S, Almer SH. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival: an 18-year experience. Liver Int. 2009;29:253-259.
66. Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009;50: 195-203.
67. Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med. 2008; 66:334-339.
68. Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151: 167-175.
69. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12:2115-2119.
70. Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med. 2009;67:46-53.
71. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587-591. (Pubitemid 30118625)
72. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a casecontrol study. Blood. 2000;96:2364-2368.
73. Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51: 210-218.
74. Smalberg JH, Darwish Murad S, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006;91: 1712-1713. (Pubitemid 46032973)
75. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell'era A, Pappalardo E, Mannucci PM. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41: 603-608. (Pubitemid 40289509)
76. Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, Guardascione MA, Margaglione M. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinolysis. 2008;19:459-462.
77. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, Erlinger S, Valla DC. Factor V Leiden related Budd-Chiari syndrome. Gut. 2001;48:264-268. (Pubitemid 32141854)
78. Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, Zalcberg IR, Spector N. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55: 1770-1777.
79. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55-61. (Pubitemid 44921067)
80. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost. 2008;99:675-682. (Pubitemid 351694223)
81. Orr DW, Patel RK, Lea NC, Westbrook RH, O'Grady JG, Heaton ND, Pagliuca A, Mufti GJ, Heneghan MA. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther. 2010;31:1330-1336.
82. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PG DEG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
83. Brandenburg VM, Frank RD, Wasmuth HE, Gartung C. Elevated levels of factor VIII:C as a possible risk factor for portal, splenic, and mesenteric vein thrombosis. Gastroenterology. 2001;120:1563-1564. (Pubitemid 32322334)
84. Koshy A, Jeyakumari M. High FVIII level is associated with idiopathic portal vein thrombosis in South India. Am J Med. 2007;120:552 e559-e511.
85. Shah SR, DasGupta A, Sharma A, Joshi A, Desai D, Abraham P, Rathi P, Bapat M. Thrombophilic conditions in non-cirrhotic portal vein thrombosis. Indian J Gastroenterol. 2005;24:205-210. (Pubitemid 44317705)
86. Martinelli I, Primignani M, Aghemo A, Reati R, Bucciarelli P, Fabris F, Battaglioli T, Dell'Era A, Mannucci PM. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol. 2009;50: 916-922.
87. Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, Hadengue A, Erlinger S, Valla D. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490-497. (Pubitemid 32147646)
88. de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost. 2007;97:181-185. (Pubitemid 46592136)
89. Frere C, Tregouet DA, Morange PE, Saut N, Kouassi D, Juhan-Vague I, Tiret L, Alessi MC. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood. 2006;108:1562-1568. (Pubitemid 44316122)
90. Guimaraes AH, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost. 2005;3: 1284-1292. (Pubitemid 41725254)
91. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem. 2002;277:1021-1030. (Pubitemid 34968847)
92. Dayal S, Pati HP, Sharma MP. Tissue plasminogen activator and plasminogen activator inhibitor status in Budd-Chiari syndrome. Haemostasis. 1996;26:284-287. (Pubitemid 26319974)
93. Hoekstra J, Guimaraes AH, Leebeek FW, Darwish Murad S, Malfliet JJ, Plessier A, Hernandez-Guerra M, Langlet P, Elias E, Trebicka J, Primignani M, Garcia-Pagan JC, Valla DC, Rijken DC, Janssen HL. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood. 2010;115:388-395.
94. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708-714. (Pubitemid 46563568)
95. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922-4929.
96. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528-1534. (Pubitemid 44953658)
97. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6:627-637.
98. Janssen HL, Leebeek FW. JAK2 mutation: the best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology. 2006;44:1391-1393. (Pubitemid 44953641)
99. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113:5617-5623.
100. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22: 2020-2028.
101. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome: an overview. J Thromb Haemost. 2007;5:642-645. (Pubitemid 46680714)
102. Hoekstra J, Leebeek FW, Plessier A, Raffa S, Darwish Murad S, Heller J, Hadengue A, Chagneau C, Elias E, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HL. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol. 2009;51: 696-706.
103. Brodsky RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008;148:587-595. (Pubitemid 351669132)
104. Rachidi S, Musallam KM, Taher AT. A closer look at paroxysmal nocturnal hemoglobinuria. Eur J Intern Med. 2010;21:260-267.
105. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol. 2000;32:865-871. (Pubitemid 30262750)
106. Talens S, Hoekstra J, Dirkx SP, Murad SD, Trebicka J, Elias E, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW, Rijken DC, for the ENVSG. Proteomic analysis reveals that apolipoprotein a1 levels are decreased in patients with budd-chiari syndrome. J Hepatol. 2010.
107. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93-102. (Pubitemid 350301144)
108. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. Highdensity lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112:893-899. (Pubitemid 41170077)
109. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-1975. (Pubitemid 39350321)
110. Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood. 2008;112:2675-2680.
111. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, Griffin JH. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609-1614. (Pubitemid 46648646)
112. Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost. 2010;103: 1136-1144.
113. Aird WC. Vascular bed-specific thrombosis. J Thromb Haemost. 2007; 5(suppl 1):283-291. (Pubitemid 46958844)
114. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113:5246-5249.
115. Aird WC. Phenotypic heterogeneity of the endothelium: II: representative vascular beds. Circ Res. 2007;100:174-190. (Pubitemid 46208718)